Introdução: A esquizofrenia é um transtorno mental grave. Embora alguns medicamentos antipsicóticos tenham demonstrado eficácia no tratamento de sintomas positivos, não há tratamento amplamente reconhecido para sintomas negativos, o que pode causar sofrimento e prejuízo significativos para pacientes com esquizofrenia. Aqui descrevemos a fundamentação teórica e o design do estudo STARTS (Schizophrenia TreAtment with electRic Transcranial Stimulation), um ensaio clínico destinado a testar a eficácia de um tratamento não farmacológico conhecido como estimulação transcraniana por corrente contínua (ETCC) para tratar os sintomas negativos da esquizofrenia. Métodos: O estudo STARTS foi concebido como um ensaio clínico randomizado, controlado por simulação, duplo-cego, avaliando a ETCC para o tratamento dos sintomas negativos da esquizofrenia. Cem pacientes serão incluídos e submetidos a 10 sessões de ETCC sobre o córtex pré-frontal dorsolateral esquerdo (estimulação anódica) e a junção temporoparietal esquerda (estimulação catodal) durante 5 dias consecutivos. Os participantes serão avaliados através de testes clínicos e neuropsicológicos antes e após a intervenção. O desfecho primário é a mudança na pontuação da subescala negativa da Escala da Síndrome Positiva e Negativa (Positive and Negative Syndrome Scale [PANSS]) ao longo do tempo e entre os grupos. Marcadores biológicos, incluindo neurotrofinas e interleucinas do sangue, polimorfismos genéticos e excitabilidade cortical motora, também serão avaliados. Resultados: Os resultados clínicos fornecerão informações sobre a ETCC como um tratamento para os sintomas negativos da esquizofrenia, e a investigação dos biomarcadores contribuirá para uma melhor compreensão dos mecanismos de ação da ETCC. Conclusão: Nossos resultados podem trazer uma nova técnica terapêutica para o tratamento dos sintomas negativos da esquizofrenia. Registro do ensaio clínico: ClinicalTrials.gov, NCT02535676. Descritores: Esquizofrenia, terapia de estimulação elétrica, ensaio clínico randomizado, marcadores biológicos, estimulação transcraniana.
Introduction
Schizophrenia is a severe mental illness that significantly impacts well-being. The negative symptoms of the disorder include blunted affect, apathy, avolition, and anhedonia, and are responsible for a large proportion of the disease burden. These symptoms represent an important clinical challenge, 1, 2 and several studies have associated negative symptoms with lower premorbid functionality, lower IQ, and poorer clinical outcome.
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Negative symptoms have a clinical course independent from positive symptoms, are stable or increasing in severity over time, and have an independent prognostic weight. [3] [4] [5] [6] [7] Although antipsychotic medications are an effective treatment for positive symptoms and are always recommended for schizophrenia, negative symptoms tend to persist or even worsen in the presence of antipsychotic medication treatment, and no effective treatment for negative symptoms has shown strong supportive evidence. 8 Evidence for the pathophysiology of negative symptoms points to the involvement of the dorsolateral prefrontal cortex (DLPFC), as neuroimaging studies have shown reduced metabolism in the prefrontal cortex in patients with schizophrenia both with and without medication, 9, 10 along with an inverse correlation between negative symptom severity and cerebral blood flow in the prefrontal cortex. 11 Hypoactivation of prefrontal regions also seems to be related to the presence of negative symptoms in schizophrenia. 12 These findings suggest that these areas could be a target for focal interventions by non-invasive brain stimulation, as such stimulation may improve the physiological deficits of the disorder and exert therapeutic effects.
Repetitive transcranial magnetic stimulation (rTMS)
uses alternating magnetic fields to induce an electric current in cortical tissue 13 and 100,000 U.S. dollars, the cost of a tDCS device ranges between 400 and 10,000 U.S. dollars. tDCS because both the anode and cathode must be placed on the scalp to close the circuit and allow the electric current to pass. A previous study designed to treat auditory hallucinations using this method reported a significant decrease in negative symptoms. 37 The main aim in this clinical trial is to confirm this hypothesis in a study designed specifically for the treatment of negative symptoms.
The primary objective of this study is to evaluate 
Methods
Design and study population STARTS is a randomized, double-blinded, placebocontrolled trial. Eligible patients will be recruited from 
Inclusion and exclusion criteria
This clinical trial was designed to include males and females diagnosed with schizophrenia according to the Potential participants will be screened by a trained psychiatrist to ensure fulfillment of all inclusion criteria.
In addition to the PANSS, the Structured Clinical Interview
for DSM-IV (SCID) will be applied during the screening interview to confirm the diagnosis of schizophrenia.
Patients will only be included if they present a minimum score of 20 points in the sum of the negative symptoms' months, use of benzodiazepines in doses equal to or higher than 10 mg of diazepam or the equivalent, and the presence of specific contraindications to tDCS such as electronic or metal implants in the cephalic segment.
We will include any stage of the disease provided the patient is under stable psychotropic medication and dosage for at least 6 weeks.
Recruitment strategies include a convenience sample of patients with schizophrenia from outpatient and inpatient clinics referred and screened by psychiatrists specialized in psychotic disorders, and spontaneous enrollment through advertisements in local newspapers, radio stations, and websites.
Measurement of variables and outcomes
Demographic and clinical profiles will be assessed The primary outcome will be measured with the PANSS negative symptoms subscale. 38 The PANSS will also be used categorically to separate subjects into responders (≥ 20% reduction in scale) and nonresponders (< 20% improvement in scale).
Each participant will be evaluated at baseline, at day 5, week 2, week 4, week 6, and week 12 ( Table 1 ). The PANSS, Auditory Verbal Hallucinations Scale (AVHS),
and Calgary Depression Scale for Schizophrenia (CDSS)
will be applied at all evaluations and at baseline.
We will apply the Scale for Assessment of Negative baseline and at week 6. We will use a tDCS questionnaire for adverse effects to assess treatment tolerability. 39 Blinding efficacy will be assessed at endpoint by asking raters and participants to guess their allocation group.
Randomization and allocation
Randomization will be generated through the website www.randomization.com and will be performed in blocks to allow permutation of block size and order.
Patient allocation will be carried out using sealed, opaque, patterned envelopes, labeled with a random number assigned to the participant. The envelope will be opened and the participant will receive either active or sham treatment according to the code contained in the envelope upon signature of the informed consent form and inclusion in the trial.
Intervention
A tDCS session involves the placement of two electrodes over the scalp. The anode will be positioned over the area corresponding to the left DLPFC, between F3 and FP1, and the cathode will be positioned over the area of the left temporoparietal junction (CP5).
The minimum distance between electrodes is 7 cm, the electrode dimensions are 5 × 7 cm, and the applied current will be 2 mA. We will use the DC Stimulator tDCS device (Neuroconn©, Ilmenau, Germany) in study mode for double-blind trials. Each session will last 20 minutes, and participants will receive two sessions a day over 5 consecutive days (Monday to Friday).
Blinding
This is a double-blind study: researchers, tDCS technicians, and patients will have no knowledge of the treatment administered to each participant until the end of the study. Technicians will not be allowed to assess the participants.
The tDCS technique is particularly advantageous for ensuring blinding when compared to other noninvasive brain stimulation techniques, as the session provokes only a mild tingling sensation which is habituated in seconds. Given this feature, sham stimulations were designed to deliver only a few seconds of electric current in the beginning of the session and then shut down and provide no electric current for the rest of the session, simulating an active session but providing no clinical or physiological effects.
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The tDCS device set on study mode requires the technician to enter one of 200 5-digit codes into the device before the session, corresponding to either an active session with parameters as described above, or a sham session. Each participant will be assigned a code according to the intervention group to which they were assigned, found in the randomization envelope. The correspondence between the participant's code and the intervention delivered will remain unknown to the team and the participants, preserving blinding.
Sample size calculation
Sample size calculation is based on the PANSS negative symptom score, which is the primary outcome of our study. In previous studies, this score has shown an average variation from 20 to 24 points in this type of patient, and a difference of 3 points is considered clinically significant. Standard deviations in previous studies have shown values between 4-5 points. 24, 38, 42 Therefore, a study with 80% power and alpha of 0.05 requires a sample of 44 patients in each group. We expect a dropout rate of 15%, suggesting an enrollment of about 50 patients per group.
Statistical analysis
Statistical analyses will be performed using Stata 12 SE programs and the Statistical Package for the Social Sciences (SPSS) version 17 for Windows. All analyses 
Motor excitability X X X CDSS = Calgary Depression Scale for Schizophrenia; PANSS = Positive and Negative Syndrome Scale; SANS = Scale for Assessment of Negative Symptoms.
will be performed according to the intention to treat principle (all patients will be included in the analysis).
We will use a general linear model with a continuous dependent variable (PANSS negative symptom score)
for the primary outcome measure. Secondary analyses will use the same model, and scores obtained on the other scales will be used as dependent variables. The analyses are considered significant at p < 0.05.
Exploratory analyses will include other variables
potentially influencing the therapeutic effect, including education, number of previous hospitalizations, presence of medical comorbidities, and other socioeconomic variables. Refractoriness to antipsychotic medication will be analyzed as a dichotomous variable, defined as presence or absence of refractoriness.
Cognitive assessments
The participants will be tested at baseline and at week 
Biological markers
Blood samples will be collected from all participants at baseline and at week 6, and the biomarkers described below will be analyzed. A portion of these samples will be frozen for posterior analysis.
a) Brain-derived neurotrophic factor (BDNF): BDNF is a neurotrophin related to synaptic strengthening, neurodevelopment, and neuroprotection, 44 and has been associated with several psychiatric disorders. BDNF gene polymorphisms are associated with better cognitive performance in patients with schizophrenia. 45 Another useful approach for studying the role of this biomarker in schizophrenia is the measurement of plasma or serum BDNF levels, as this biomarker can cross the brain-blood barrier. 44 Blood BDNF levels appear to be lower in patients with chronic schizophrenia compared to controls, 46, 47 and some studies examining BDNF levels before and after treatment found increased levels following the use of antipsychotics. 
Expected results
Our primary hypothesis is that participants receiving active tDCS will present a reduction of negative symptoms as measured by the PANSS, compared to patients receiving sham tDCS. The results of this study will additionally contribute to the development of further studies on neuromodulation for the treatment of schizophrenia.
Sources of funding
We receive financial support from Instituto Nacional 
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Discussion
The STARTS study will be one of the largest trials to date assessing the efficacy of tDCS for the treatment of schizophrenia. Our protocol consists of 10 sessions of tDCS using 2 mA for 20 min, with two sessions a day, similar to the protocol used by Brunelin et al. 56 Sample size was calculated to avoid type I and II errors and can accommodate an attrition rate of 15%. We will enroll patients with different degrees of refractoriness and variable antipsychotic medication treatments, which will significantly increase the external validity of our results. These data could contribute to the analysis of some predictors of response as well.
This trial differs from the clinical trial conducted by Brunelin et al. in several ways, including a larger sample size (100 vs. 30). We are also collecting blood samples and evaluating several additional parameters and biomarkers related to genetics, neuropsychological state, and motor excitability. We will assess depressive symptoms, medication use, and other possible variables that may influence the results, and we are using multiple scales to assess the negative symptoms (SANS). 
Conclusion
The STARTS study will investigate the efficacy of tDCS for the treatment of the negative symptoms of schizophrenia using a randomized, sham-controlled design. The biomarker investigation will contribute to the understanding of the neurobiological mechanisms of schizophrenia and their relationship with treatment.
This trial will contribute valuable information to the treatment of schizophrenia.
